(0.31%) 5 115.76 points
(0.32%) 38 360 points
(0.34%) 15 982 points
(-0.94%) $83.06
(5.51%) $2.03
(0.36%) $2 355.60
(0.42%) $27.65
(4.02%) $959.20
(-0.24%) $0.932
(-0.38%) $10.98
(-0.55%) $0.796
(1.69%) $93.43
3 days till quarter result
(tns 2024-05-02)
Expected move: +/- 13.80%
Live Chart Being Loaded With Signals
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases...
Stats | |
---|---|
本日の出来高 | 2.76M |
平均出来高 | 634 418 |
時価総額 | 135.20M |
EPS | $0 ( 2024-03-07 ) |
次の収益日 | ( $0 ) 2024-05-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -3.04 |
ATR14 | $0.0960 (14.39%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-02 | Singer Michael | Buy | 178 000 | Common Stock |
2024-01-02 | Singer Michael | Buy | 228 000 | Stock Option (Right to Buy) |
2023-12-22 | Singer Michael | Sell | 3 000 | Series A Convertible Preferred Stock |
2024-01-02 | Davis Blaine | Buy | 3 110 000 | Employee Stock Option (right to buy) |
2024-01-02 | Davis Blaine | Buy | 2 424 000 | Common Stock |
INSIDER POWER |
---|
52.95 |
Last 97 transactions |
Buy: 26 530 299 | Sell: 8 848 103 |
ボリューム 相関
Selecta Biosciences Inc 相関
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Selecta Biosciences Inc 相関 - 通貨/商品
Selecta Biosciences Inc 財務諸表
Annual | 2023 |
収益: | $0 |
総利益: | $0 (0.00 %) |
EPS: | $-0.00140 |
FY | 2023 |
収益: | $0 |
総利益: | $0 (0.00 %) |
EPS: | $-0.00140 |
FY | 2022 |
収益: | $110.78M |
総利益: | $38.40M (34.66 %) |
EPS: | $0.240 |
FY | 2021 |
収益: | $85.08M |
総利益: | $0.00 (0.00 %) |
EPS: | $-0.220 |
Financial Reports:
No articles found.
Selecta Biosciences Inc
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in preclinical stage to improve the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising SEL-313, a product candidate in preclinical stage to treat ornithine transcarbamylase deficiency; SEL-399, a product candidate to evaluate the appropriate dose of ImmTOR in humans to reduce the formation of antibodies to AAV capsids; and products for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat primary biliary cholangitis and other autoimmune diseases. The company has license and collaboration agreements with Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum; Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; Shenyang Sunshine Pharmaceutical Co., Ltd.; Ginkgo Bioworks Holdings, Inc.; and IGAN Biosciences, Inc. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。